At last, two new meds in Quebec
The CAPAHC is pleased with the Québec Ministry of Health and Social Services’ decision to add Harvoni and Holkira Pak to the list of medications that are covered by the RAMQ.
This is a turning point for patients who are struggling with hepatitis C, since both drugs show very high cure rates, while significantly reducing side effects.
But we have to stay calm, because these access for the new meds are only for patients living with fibrosis or cirrhosis F3/F4. For the first time in Québec the government opted for a management approach, so we have to wait until 4 years for an access for all the people living with hep C, with or without cirrhosis.
Please find below a table for a better understanding of the access to Harvoni and Holkira Pak in the first year: